KINGKEN PHARMACEUTICALS | 京品(柬埔寨)药业有限公司

Kingken (Cambodia) Pharmaceutical Co., Ltd.

Kingken (Cambodia) Pharmaceutical Co., Ltd. has been dealing in medicines for more than 20 years in the Kingdom of Cambodia and ASEAN. We are an authorized wholesaler & retail which has been duly licensed in accordance with the laws of the Kingdom of Cambodia.

We specialize in the import, export and sale of new medicines for all major chronic diseases including various types of cancer. Besides serving customers in ASEAN, we also provide high quality service to customers around the world. We serve a wide range of customers including hospitals, clinics, doctors, pharmacies, individual customers and biotech companies or institutes.

Hot Products

Lenvatinib
Lenvanix
Osimertinib
Tagrix
Crizotinib
Crizonix
Afatinib
Afanix
Regorafenib
Regonix
Ibrutinib
Ibrutix
Eltrombopag
Elbonix
Sunitinib
Sunitix
Axitinib
Axinix
Epclusa
Sofosvel
Everolimus
Xevirol
Trelagliptin
Wedica

New Arrivals

Lenvatinib
Lenvanix
Ibrutinib
Ibrutix
Eltrombopag
Elbonix
Sunitinib
Sunitix
Axitinib
Axinix
Trelagliptin
Wedica

Diseases

FDA approves Gilead's first all genotypic hepatitis C new drug Epclusa

June 29, 2016 - Gilead, a ubiquitous genotypic hepatitis C cocktail therapy in the field of hepatitis C, has made a major milestone in the US regulation, Epclusa. FDA has approved Epclusa for the treatment of all 6 genotypes of hepatitis C.

Hepatitis C new drug Epclusa was approved by the United States and the European Union

July 9, 2016 - the ubiquitous gene type hepatitis C cocktail therapy (Epclusa) developed by Gilead, the absolute hegemon in the field of hepatitis C, has achieved a major milestone in the United States

AZD9291 is a milestone in the development of medicine for lung cancer

Lung cancer is one of the most malignant tumors with the fastest growth rate of morbidity and mortality and the most serious threat to peoples health and life. In the past 50 years, many countries have reported that the incidence and mortal